Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

  title={Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome},
  author={Orrin Devinsky and Anup D. Patel and Elizabeth A. Thiele and Matthew H. Wong and Richard E Appleton and Cynthia Harden and Sam Greenwood and Gilmour Morrison and Kenneth W. Sommerville},
  pages={e1204 - e1211}
Objective To evaluate the safety and preliminary pharmacokinetics of a pharmaceutical formulation of purified cannabidiol (CBD) in children with Dravet syndrome. Methods Patients aged 4–10 years were randomized 4:1 to CBD (5, 10, or 20 mg/kg/d) or placebo taken twice daily. The double-blind trial comprised 4-week baseline, 3-week treatment (including titration), 10-day taper, and 4-week follow-up periods. Completers could continue in an open-label extension. Multiple pharmacokinetic blood… 

Figures and Tables from this paper

Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy

Inter-individual variability in systemic cannabidiol exposure after pediatric patient treatment with cannabdiol oral solution was observed but decreased with multiple doses, and short-term administration was generally safe and well tolerated.

Adjunctive Cannabidiol in Patients with Dravet Syndrome: A Systematic Review and Meta-Analysis of Efficacy and Safety

Adjunctive CBD resulted in a greater reduction in convulsive seizure frequency than placebo and a higher rate of AEs in patients with DS presenting with seizures uncontrolled by concomitant antiepileptic therapy.

Slow Titration of Cannabidiol Add-On in Drug-Resistant Epilepsies Can Improve Safety With Maintained Efficacy in an Open-Label Study

A slower titration of CBD dose delivered better tolerance with comparable efficacy to previous trials and should help guide clinicians prescribing CBD and allow patients to benefit from its potential efficacy.

An Open Retrospective Study of a Standardized Cannabidiol Based-Oil in Treatment-Resistant Epilepsy

The efficacy of a CBD-based oil formulation with few significant side effects in patients with treatment-resistant epilepsy of various etiologies was showed.

Cannabidiol in Pharmacoresistant Epilepsy: Clinical Pharmacokinetic Data From an Expanded Access Program

These are the first data on CBD pharmacokinetics in children and adults with LGS or DS in a real-world setting and the most relevant finding was the higher CBD C/D in adults.

Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials

Evaluated SAEs related to CBD in RCT are mainly elevated transaminases, convulsion, sedation, lethargy, and upper respiratory tract infections that are related to concomitant clobazam use and should be monitored when using CBD concomitantly with these and other antiepileptic drugs.



Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy

The efficacy of low-dose CLB therapy was significantly influenced by CYP2C19 polymorphisms and dosage should be started with a low dose and dosage increased until N-CLB serum concentration reaches 1100 ng/mL or until the desired effect is acquired, a recommendation that is particularly important for PMs.

Human Cannabinoid Pharmacokinetics

  • M. Huestis
  • Biology, Chemistry
    Chemistry & biodiversity
  • 2007
The cardiovascular and subjective effects of cannabis are blocked by rimonabant, the first CB-1 cannabinoid-receptor antagonist, documenting thatCB-1 receptors mediate these effects of smoked cannabis in humans.

Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy

Under an expanded access investigational new drug (IND) trial, cannabidiol (CBD) is being studied as a possible adjuvant treatment of refractory epilepsy in children, and it is predicted a drug–drug interaction.

Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases

Cannabidiol is added as a possible treatment for febrile infection-related epilepsy syndrome who had not responded to antiepileptic drugs or other therapies who were given cannabadiol on emergency or expanded investigational protocols in either the acute or chronic phase of illness.

Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review

In vitro data were identified that characterize cytochrome P-450 (CYP-450) enzymes as potential significant contributors to the primary metabolism of several exogenous cannabinoids, and clinical pharmacogenetic data further support CYP2C9 as a significant contributor to THC metabolism, and a pharmacokinetic interaction study using ketoconazole with oromucosal cannabis extract further supports CYP3A4 as asignificant metabolic pathway for THC and CBD.

Interactions between cannabidiol and commonly used antiepileptic drugs

To identify potential pharmacokinetic interactions between the pharmaceutical formulation of cannabidiol (CBD; Epidiolex) and the commonly used antiepileptic drugs (AEDs) through an open‐label safety

Cannabidiol as a new treatment for drug‐resistant epilepsy in tuberous sclerosis complex

CBD, a nonpsychoactive compound derived from the marijuana plant, is evaluated as an adjunct to current antiepileptic drugs in patients with refractory seizures in the setting of TSC.

Cannabinoids in the Treatment of Epilepsy.

The pharmacologic and biochemical features of cannabinoids make them candidates for antiseizure medications. At this time, anecdotes have outstripped controlled clinical trials as sources of support